Table 1 Proportion of patients developing IgG antibodies and neutralizing capacity against SARS-CoV-2 after infection and vaccination
Infected | Vaccinated | Â | |||
|---|---|---|---|---|---|
| Â | N | N (%) | N | N (%) | p-value |
IgG antibodies against RBD | |||||
 Overall | 69 | 65 (94.2) | 326 | 260 (79.7) | 0.004 |
 KTR | 22 | 19 (86.4) | 129 | 72 (55.8) | 0.007 |
 HD | 24 | 23 (95.8) | 85 | 76 (89.4) | 0.45 |
 Control | 23 | 23 (100.0) | 112 | 112 (100.0) | * |
IgG antibodies against S1S2 | |||||
 Overall | 69 | 65 (94.2) | 326 | 248 (76.1) | 0.001 |
 KTR | 22 | 19 (86.4) | 129 | 60 (46.5) | 0.001 |
 HD | 24 | 23 (95.8) | 85 | 76 (89.4) | 0.45 |
 Control | 23 | 23 (100.0) | 112 | 112 (100.0) | - |
IgG antibodies against NP | |||||
 Overall | 69 | 66 (95.7) |  | NA |  |
 KTR | 22 | 20 (90.9) |  | NA |  |
 HD | 24 | 23 (95.8) |  | NA |  |
 Control | 23 | 23 (100.0) |  | NA |  |
Neutralizing capacity | |||||
 Overall | 69 | 62 (89.9) | 152 | 145 (95.4) | 0.14 |
 KTR | 22 | 20 (90.9) | 21 | 17 (80.9) | 0.41 |
 HD | 24 | 23 (95.8) | 24 | 21 (87.5) | 0.61 |
 Control | 23 | 19 (82.6) | 107 | 107 (100.0) | 0.001 |